Cutaneous T-cell lymphoma · 3 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Busulfan and Fludarabine, then allo HSCT Variant #08 | — | R 19 257 | — | 9.0 mo | — | — | — | 1 |
Fludarabine and Melphalan, then allo HSCT Variant #02 | — | R 12 678 | — | 9.0 mo | — | — | — | 1 |
Busulfan, Fludarabine, Thiotepa, then allo HSCT N/A - secondary systemic drug | — | R 980 | — | 9.0 mo | — | — | — | 1 |
3 of 3 regimens shown